BMY

US FDA Approves OPDIVO in Combination with CABOMETYX as First-line Treatment for Patients with Advanced Renal Cell Carcinoma

Bristol-Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Bristol Myers Squibb is poised for double-digit growth in 2020, thanks to its acquisition of Celgene. And, BMY stock is now trading near a five-year high. So, is BMY stock a buy?

Although the share price performance could not be more different, the long-term fundamentals of both companies are very strong. Bristol-Myers Squibb is a big pharma company with a drug portfolio and research pipeline more akin to a high-growth biotech. Pinterest, on the other hand, is revolutionizing the social media space.

ARK Investment has attracted many investors, thanks to its focus on innovative companies. But it now owns too much of some companies, which could limit its ability to select and trade stocks freely.

Bristol Myers Squibb Announces Earnings Call Time Change; Fourth Quarter 2020 Earnings Call to Occur on February 4, 2021 at 10 a.m. (Eastern Time)

US FDA Accepts for Priority Review Application for Opdivo Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer....

U.S. FDA Accepts for Priority Review Application for Opdivo as Adjuvant Therapy for Patients w/Resected Esophageal or Gastroesophageal Junction Cancer

Company's R&D aimed at cell replacement therapy for range of diseases

Bristol-Myers Squibb (BMY) closed the most recent trading day at $66.54, moving +0.79% from the previous trading session.

Wedgewood Partners recently released its Q4 2020 Investor Letter, a copy of which you can download here. The Fund returned 12.2% for the fourth quarter of 2020. Meanwhile, the benchmark S&P 500 Index and the Russell 1000 Growth Index gained 12.2% and 11.4%, respectively. You should check out Wedgewood Partners’ top 5 stock picks for […]

Over the past three months, shares of Bristol-Myers Squibb (NYSE: BMY) moved higher by 8.86%. Before having a look at the importance of debt, let us look at how much debt Bristol-Myers Squibb has.Bristol-Myers Squibb's Debt According to the Bristol-Myers Squibb's most recent financial statement as reported on November 5, 2020, total debt is at $44.95 billion, with $41.36 billion in long-term debt and $3.58 billion in current debt. Adjusting for $19.43 billion in cash-equivalents, the company has a net debt of $25.51 billion.Let's define some of the terms we used in the paragraph above. Current debt is the portion of a company's debt which is due within 1 year, while long-term debt is the portion due in more than 1 year. Cash equivalents include cash and any liquid securities with maturity periods of 90 days or less. Total debt equals current debt plus long-term debt minus cash equivalents.To understand the degree of financial leverage a company has, investors look at the debt ratio. Considering Bristol-Myers Squibb's $125.54 billion in total assets, the debt-ratio is at 0.36. As a rule of thumb, a debt-ratio more than one indicates that a considerable portion of debt is funded by assets. A higher debt-ratio can also imply that the company might be putting itself at risk for default, if interest rates were to increase. However, debt-ratios vary widely across different industries. A debt ratio of 25% might be higher for one industry and average for another.Importance Of Debt Besides equity, debt is an important factor in the capital structure of a company, and contributes to its growth. Due to its lower financing cost compared to equity, it becomes an attractive option for executives trying to raise capital.However, due to interest-payment obligations, cash-flow of a company can be impacted. Having financial leverage also allows companies to use additional capital for business operations, allowing equity owners to retain excess profit, generated by the debt capital.Looking for stocks with low debt-to-equity ratios? Check out Benzinga Pro, a market research platform which provides investors with near-instantaneous access to dozens of stock metrics - including debt-to-equity ratio. Click here to learn more.See more from Benzinga * Click here for options trades from Benzinga * AutoNation's Debt Overview * Recap: JPMorgan Chase Q4 Earnings(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Beigene stock broke out and surged to a record high Thursday after China's regulators approved its lung cancer treatment. Earlier this week, Novartis signed on to commercialize the drug.

Company cutting debt to increase ability to make deals and boost shareholder return

Bristol-Myers Squibb (BMY) closed the most recent trading day at $65.43, moving +0.71% from the previous trading session.

The drugmaker expects its current pipeline of drugs could generate $25 billion in annual revenue and sees opportunities for more acquisitions.

Beigene stock jumped Tuesday on a cancer drug development deal with Novartis worth up to $2.2 billion, as Vir Biotechnology also announced a hepatitis B tie-up with Gilead Sciences.

For his second "Executive Decision" segment of Mad Money Monday evening, Jim Cramer spoke with Giovanni Caforio, CEO of Bristol-Myers Squibb , the drug maker that saw its shares up 4% Monday after presenting at the annual JP Morgan Healthcare Conference. Caforio commented on Bristol's $13 billion acquisition of MioKardia, saying the company's drug Eliquis is "first in class" and expands their leadership position in the cardiovascular space. Caforio noted that Bristol has strong free cash flows.

Bristol Myers Squibb (NYSE: BMY) has upsized its stock buyback program by 45%. As is typical with such announcements, Bristol Myers added a caveat: "The timing and amount of any share repurchases under the authorization will be determined by management at its discretion and based on market conditions and other considerations." In recent years, Bristol Myers has hardly been shy about supporting its share price with buybacks.

Eli Lilly stock rocketed to a record high Monday after the pharmaceutical company said its experimental drug slowed cognitive decline in a Phase 2 test of patients with Alzheimer's disease.